Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 249 | 20 | 228 |
| Samples | 150 | 19 | 130 |
| Peptides | 115 | 18 | 96 |
Function
CRLF2 · Cytokine receptor like factor 2
This gene encodes a member of the type I cytokine receptor family. The encoded protein is a receptor for thymic stromal lymphopoietin (TSLP). Together with the interleukin 7 receptor (IL7R), the encoded protein and TSLP activate STAT3, STAT5, and JAK2 pathways, which control processes such as cell proliferation and development of the hematopoietic system. Rearrangement of this gene with immunoglobulin heavy chain gene (IGH) on chromosome 14, or with P2Y purinoceptor 8 gene (P2RY8) on the same X or Y chromosomes is associated with B-progenitor acute lymphoblastic leukemia (ALL) and Down syndrome ALL. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Sep 2014].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 109 amino-acid changes on canonical ENST00000400841 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CRLF2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CRLF2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Endometrial Carcinoma | 0/42 0% | 10/612 2% |
| Melanoma | 0/210 0% | 20/1899 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 7/810 1% |
| Small Cell Lung Carcinoma | 1/9 11% | 5/752 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Cervical Carcinoma | 0/35 0% | 3/422 1% |
| Gastric Carcinoma | 1/74 1% | 11/1809 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 10/1592 1% |
| Colorectal Carcinoma | 8/143 6% | 11/3239 0% |
| Other Sarcomas | 0/69 0% | 4/699 1% |
| Non-Small Cell Lung Carcinoma | 3/304 1% | 5/1390 0% |
| Non-Cancerous | 0/104 0% | 4/830 0% |
| B-Lymphoblastic Leukemia | 1/55 2% | 10/2640 0% |
| Bladder Carcinoma | 1/58 2% | 3/956 0% |
| Meningioma | 0/3 0% | 1/252 0% |
| Glioma | 0/52 0% | 7/2127 0% |
| Neuroendocrine Tumour | 1/154 1% | 1/577 0% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 5/2550 0% |
| Hepatocellular Carcinoma | 0/46 0% | 3/2210 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
| Other Solid Cancers | 1/94 1% | 1/1515 0% |
| Biliary Tract Carcinoma | 0/54 0% | 1/950 0% |
| Neuroblastoma | 0/87 0% | 1/1331 0% |
| Other Blood Cancers | 0/61 0% | 2/2725 0% |
| Head and Neck Carcinoma | 0/85 0% | 1/1574 0% |
| Prostate Carcinoma | 0/13 0% | 1/2105 0% |
| Kidney Carcinoma | 0/85 0% | 1/1862 0% |
| B-Cell Non-Hodgkins Lymphoma | 1/88 1% | 0/2534 0% |
| Breast Carcinoma | 0/144 0% | 1/3264 0% |
Mutation Distribution
Where CRLF2 is mutated · all tissues, split by cell line vs tissue
How many mutations in CRLF2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 42 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 249 mutations in CRLF2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|